2026 Global: Chip-Sequencing Market-Competitive Review (2032) report
Description
The 2026 Global: Chip-Sequencing Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for chip-sequencing market by geography and historical trend. The scope of the report extends to sizing of the chip-sequencing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Illumina leads the ChIP-Sequencing market as a dominant force with its iScan System and BeadChip arrays, enabling high-throughput SNP genotyping and genomic analysis integral to ChIP workflows. Thermo Fisher Scientific follows closely, providing integrated solutions like the GeneTitan Multi-Channel System, Clariom D arrays for gene expression, and CytoScan HD Accel for cytogenetics, supporting ChIP applications in precision medicine and pharmacogenomics. Agilent Technologies excels in microarray platforms compatible with ChIP-seq, offering customizable high-density arrays for epigenomic studies and genetic variation detection. These U.S.-based giants leverage complementary next-generation sequencing (NGS) technologies, where Illumina's NovaSeq systems process ChIP libraries with unmatched scalability, while Thermo Fisher advances automated workflows for ChIP-derived data analysis.
Arrayit Corporation specializes in comprehensive DNA microarray platforms, reagents, and services tailored for ChIP-related gene expression, genotyping, and diagnostics, including NanoPrint systems for custom chip production. Bio-Rad Laboratories contributes robust microarray solutions with a 5.1% share in biological chips, enhancing ChIP-seq through reliable consumables and imaging tools for epigenetic research. Merck KGaA (and Merck & Co.) supports ChIP applications via advanced arrays and NGS reagents for biomarker discovery and single-cell epigenomics, bolstering high-throughput ChIP processing. PerkinElmer provides precision instruments for ChIP-seq sample preparation, while Molecular Devices offers scanning and analysis systems to interpret ChIP-enriched DNA sequences accurately.
Macrogen delivers sequencing services optimized for ChIP-seq, enabling global researchers to profile protein-DNA interactions efficiently, and CapitalBio Corporation innovates with specialized chips for genomic applications overlapping ChIP studies. BD (Becton Dickinson) strengthens the market through single-cell tools like the Rhapsody system, facilitating ChIP-seq in complex tissues for immunology and oncology insights. 10x Genomics rounds out the top ten with its Chromium platform, revolutionizing ChIP-seq by enabling high-throughput single-cell epigenomic profiling via GEM-X kits compatible with leading sequencers. Collectively, these companies drive ChIP-Sequencing innovation, merging microarray heritage with NGS for deeper epigenetic understanding.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for chip-sequencing market by geography and historical trend. The scope of the report extends to sizing of the chip-sequencing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Illumina leads the ChIP-Sequencing market as a dominant force with its iScan System and BeadChip arrays, enabling high-throughput SNP genotyping and genomic analysis integral to ChIP workflows. Thermo Fisher Scientific follows closely, providing integrated solutions like the GeneTitan Multi-Channel System, Clariom D arrays for gene expression, and CytoScan HD Accel for cytogenetics, supporting ChIP applications in precision medicine and pharmacogenomics. Agilent Technologies excels in microarray platforms compatible with ChIP-seq, offering customizable high-density arrays for epigenomic studies and genetic variation detection. These U.S.-based giants leverage complementary next-generation sequencing (NGS) technologies, where Illumina's NovaSeq systems process ChIP libraries with unmatched scalability, while Thermo Fisher advances automated workflows for ChIP-derived data analysis.
Arrayit Corporation specializes in comprehensive DNA microarray platforms, reagents, and services tailored for ChIP-related gene expression, genotyping, and diagnostics, including NanoPrint systems for custom chip production. Bio-Rad Laboratories contributes robust microarray solutions with a 5.1% share in biological chips, enhancing ChIP-seq through reliable consumables and imaging tools for epigenetic research. Merck KGaA (and Merck & Co.) supports ChIP applications via advanced arrays and NGS reagents for biomarker discovery and single-cell epigenomics, bolstering high-throughput ChIP processing. PerkinElmer provides precision instruments for ChIP-seq sample preparation, while Molecular Devices offers scanning and analysis systems to interpret ChIP-enriched DNA sequences accurately.
Macrogen delivers sequencing services optimized for ChIP-seq, enabling global researchers to profile protein-DNA interactions efficiently, and CapitalBio Corporation innovates with specialized chips for genomic applications overlapping ChIP studies. BD (Becton Dickinson) strengthens the market through single-cell tools like the Rhapsody system, facilitating ChIP-seq in complex tissues for immunology and oncology insights. 10x Genomics rounds out the top ten with its Chromium platform, revolutionizing ChIP-seq by enabling high-throughput single-cell epigenomic profiling via GEM-X kits compatible with leading sequencers. Collectively, these companies drive ChIP-Sequencing innovation, merging microarray heritage with NGS for deeper epigenetic understanding.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.